Beta Bionics, Inc.

Some of the limitations of adjusted EBITDA include: (i) adjusted EBITDA does not properly reflect capital commitments to be paid in the future and (ii) although depreciation and amortization expense are non-cash charges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these capital expenditures.

SEC original ↗Beta Bionics, Inc. — Earnings release (8-K exhibit)EX-99Feb 17, 2026

When available, the Company uses the rate implicit in the lease to discount lease payments to present value; otherwise, the Company estimates the incremental borrowing rate to discount the lease payments based on information available at lease commencement (see Note 14).

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026

Treasury securities 45,411 20 45,431 Total $ 232,578 $ 402 $ $ 232,980 As of September 30, 2026 , all available-for-sale debt securities in an unrealized loss position had been in a continuous unrealized loss position for less than 12 months.

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026

There were no available-for-sale debt securities in an unrealized loss position as of December 31, 2025.

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026

The Company did not record an allowance for credit losses on its available-for-sale debt securities because the unrealized losses were primarily attributable to changes in market interest rates and not credit deterioration.

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026

The following represents the contractual maturities of available-for-sale debt securities as of September 30, 2026: Fair Value Measurements at September 30, 2026 Years to Maturity Within One One to Two More Than Two Estimated Year Years Years Fair Value (in thousands) U.

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026

Recent Strategic Highlights Completed first-in-human Phase 2a feasibility trial in New Zealand for the bihormonal system in development, including the glucagon asset, pump, and dosing algorithms.

SEC original ↗Beta Bionics, Inc. — Earnings release (8-K exhibit)EX-99Feb 17, 2026

As we look ahead to 2026, we believe the company is well-positioned to grow its leadership in the durable insulin pump market while advancing our pipeline initiatives that have clear potential to revolutionize care for people with diabetes in the years to come.

SEC original ↗Beta Bionics, Inc. — Earnings release (8-K exhibit)EX-99Feb 17, 2026

All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations, financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements.

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026

(the Company ) is a commercial-stage medical device company focused on the design, development and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) through the use of adaptive closed-loop algorithms.

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026

The Company calculates adjusted EBITDA as net loss adjusted to exclude (i) depreciation expense, (ii) stock-based compensation expense, (iii) interest income, (iv) income tax expense, (v) change in fair value of warrant liabilities, (vi) litigation settlement and other related expense, and (vii) other non-recurring expense.

SEC original ↗Beta Bionics, Inc. — Earnings release (8-K exhibit)EX-99Feb 17, 2026

In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur.

SEC original ↗Beta Bionics, Inc. — Earnings release (8-K exhibit)EX-99Feb 17, 2026

Legal Proceedings 43 Item 1A.

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026

Exhibits 51 Signatures 52 1 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this Quarterly Report) contains forward-looking statements about us and our industry that involve substantial risks and uncertainties.

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026

These forward-looking statements are subject to a number of risks, uncertainties, factors and assumptions described under Part II.

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026

Revenue The Company disaggregates net sales by product category and reimbursement channel, which the Company believes provides a meaningful depiction of how the nature, timing and uncertainty of net sales are affected by economic factors.

SEC original ↗Beta Bionics, Inc. — 10-Q Quarterly report10-QOct 27, 2026